Grifols marked a 3.9% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $10.9? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
-
Grifols belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19
-
The company's P/B ratio is 1.32
-
Grifols has a trailing 12 month Price to Earnings (P/E) ratio of 40.4 based on its trailing 12 month price to earnings (EPS) of $0.27 per share
-
Its forward P/E ratio is 9.7, based on its forward earnings per share (EPS) of $1.12
-
Over the last four years, Grifols has averaged free cash flows of $-46211666.7, which on average grew 76.3%
-
GRFS's gross profit margins have averaged 40.3 % over the last four years and during this time they had a growth rate of -2.4 % and a coefficient of variability of 13.58 %.
-
Grifols has moved 40.6% over the last year compared to 15.4% for the S&P 500 -- a difference of 25.2%
-
GRFS has an average analyst rating of buy and is -10.5% away from its mean target price of $12.19 per share